在泰国一家三级护理医院进行的顺铂和通用拓扑替康治疗晚期和复发性宫颈癌的结果：回顾性分析。
Outcomes of advanced and recurrent cervical cancer treated with cisplatin and generic topotecan: retrospective analysis in a tertiary care hospital in Thailand.
机构信息
Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Chiang Mai University Faculty of Medicine, Chiang Mai, Thailand.
出版信息
J Gynecol Oncol. 2010 Dec 30;21(4):237-40. doi: 10.3802/jgo.2010.21.4.237. Epub 2010 Dec 31.
OBJECTIVE
Retrospective evaluation of the outcome of stage IVB, recurrent or persistent cervical cancer treated with cisplatin and generic topotecan (CT) in a tertiary care hospital in Thailand.
METHODS
The medical records of patients treated with CT regimen at Chiang Mai University Hospital between January 2005 and December 2007 were reviewed and analyzed. The treatment protocol consisted of IV topotecan 0.75 mg/m(2) on days 1, 2, and 3; combined with cisplatin 50 mg/m(2) IV on day 1 and repeated every 21 days until progression or unacceptable toxicity for a maximum of 6 cycles. The outcomes were evaluated based on the response rate, progression free survival (PFS), and overall survival (OS) by using the World Health Organization criteria. The adverse effects of the treatments were also determined.
RESULTS
Twenty-one cervical cancer patients received the CT regimen. The tumor response rate was 28.6%. The median PFS and OS was 4 and 11 months, respectively. With 87 cycles of chemotherapy, the most common grade 3 & 4 hematologic toxicity was neutropenia (57.9%).
CONCLUSION
Advanced and recurrent cervical cancer patients treated with cisplatin and generic topotecan had a favorable outcome with manageable toxicity.
目的
回顾性评估在泰国一家三级护理医院接受顺铂和通用拓扑替康（CT）治疗的 IVB 期、复发性或持续性宫颈癌患者的结局。
方法
对 2005 年 1 月至 2007 年 12 月在清迈大学医院接受 CT 方案治疗的患者的病历进行了回顾性分析。治疗方案包括 IV 拓扑替康 0.75 mg/m²，第 1、2 和 3 天；联合顺铂 50 mg/m²，第 1 天静脉注射，每 21 天重复一次，直到进展或不可接受的毒性，最多 6 个周期。根据世界卫生组织标准，采用反应率、无进展生存期（PFS）和总生存期（OS）评估结果。还确定了治疗的不良反应。
结果
21 例宫颈癌患者接受了 CT 方案治疗。肿瘤反应率为 28.6%。中位 PFS 和 OS 分别为 4 个月和 11 个月。接受 87 个周期的化疗，最常见的 3 级和 4 级血液学毒性为中性粒细胞减少症（57.9%）。
结论
接受顺铂和通用拓扑替康治疗的晚期和复发性宫颈癌患者的结局良好，毒性可管理。
Zotero 插件